

Document Detail

Туре:	PMF IBTS SPEC
Document No.:	IBTS/PMF/SPEC/0224[3]
Title:	CRYOPRECIPITATE SUITABLE FOR NEONATAL USE
Owner:	QA DOC CON QA DOC CONTROL
Status	CURRENT
Effective Date:	18-Apr-2021
Expiration Date:	18-Apr-2023

Review

Review: IBTS PMF REVIEW

Level	Owner Role	Actor	Sign-off By
1	DOCUMENT CONTROLLER	REBECCA WALDEN	REBECCA WALDEN
2	QUALITY ASSURANCE WRITER IBTS	REBECCA WALDEN	REBECCA WALDEN
3	LABS HEAD OF MANUFACTURING & ISSUE IBTS	BARRY DOYLE	BARRY DOYLE
3	NATIONAL MEDICAL DIRECTOR	STEPHEN FIELD	STEPHEN FIELD
4	QUALITY ASSURANCE REVIEWER IBTS	COLIN JOHNS	COLIN JOHNS

Change Orders

Changes as described on Change Order: Change Order No.

Change Orders - Incorporated

Changes as described on Change Order:

Change Order No. IBTS/CO/0167/21

IRISH BLOOD TRANSFUSION SERVICE

PRODUCT MASTER FILE

TITLE: CRYOPRECIPITATE SUITABLE FOR NEONATAL USE

Change Description:

Revise IBTS/PMF/SPEC/0203 - 0218, 0220, 0221, 0224, 0226, 0227, 0232, 0236 to update the product labels in the appendices for each product.

Reason for Change:

Fix to the labels as part of the semester patch reference CC 126/19/IBTS and reference se. status IBTS/QA/IQ/0600 Deviation 008

Change order No.: IBTS/CO/0167/21

Referenced Documents BT - 0457

SmartSolve Roles N/A

Training Type N/A

SmartSolve Document Category

Category	Mobile	Cryobiology	Website	GDP
Yes / No	No	No	Yes	No
10,				

IRISH BLOOD TRANSFUSION SERVICE

PRODUCT MASTER FILE

Title:Cryoprecipitate Suitable for Neonatal Use

Name of Product:CRYOPRECIPITATE, Suitable for Neonatal Use

E Progesa Codabar Component Code : 80160

E Progesa ISBT-128 Component Code : C6296V00

General Description:

Cryoprecipitate, Suitable for Neonatal use contains the major portion of Factor VIIIc, von Willebrand factor, fibrinogen, Factor XIII and fibronectin from a unit of Fresh Frozen Plasma. The selected donors meet the additional criteria for neonatal use. Prepared from male donors only. The parent donation is filtered as whole blood.

General Specification:

Parameter	Quality Requirement	Frequency of Control
Volume	30 - 40 ml	100 %
Factor VIIIc	> 70 IU/unit	1%
Fibrinogen	>140 mg/unit	1%
Von Willebrand Factor	>100 IU/unit	1%
ABO Agglutinins	No HighTitre Anti-A or Anti-B	100%
CMV	CMV ab negative	100%

Labelling: See Appendices I and II.

Storage: Cryoprecipitate should be stored at a core temperature of $\leq -25^{\circ}$ C, for a maximum of 12 months. Once thawed, the component must not be refrozen and should be used immediately. If delay is unavoidable, the component should be stored at ambient temperature and used within 6 hours.

IBTS/PMF/SP	EC/0224	Ver 3	Page 4 of 7
Transportation:	should be mai Blood Transfu Cryoprecipita	ntained $\leq -25^{\circ}$ C du usion Service to the te is to be thawed fo	ort container for Cryoprecipitate uring transportation from The Irish place intended for use. Unless r immediate therapeutic use, it to storage at $\leq -25^{\circ}$ C.
Indications for Use:	 Quantitative and Qualitative disorders of fibrinogen such as acquired hypofibrinogenaemia in disseminated intravascular coagulopathy and following large volume transfusion. Cryoprecipitate should be thawed in a properly controlled environment at 37°C immediately after removal from storage and immediately before use. Dissolving of the precipitate should be encouraged by careful manipulation during the thawing procedure. The integrity of the pack should be verified to exclude any defects or leakage. 		
Precautions In Use:			
	• Cryoprec	ipitate should not be	e refrozen.
	Cryoprec containin	ipitate should be inf g an inline 170-200	used intravenously through a set μm filter.
Adverse Effects Inclu	ude:		
	Non Haer	ible plasma in the co nolytic transfusion	on due to transfusion of ABO- omponent. reactions - chills, fever,
Jerify when "	• <u>Metabolic</u> - Citra wher		s with impaired hepatic function or rapidly transfused.
	• <u>Immunol</u> - Alloi - Tran	ogical effects munisation to HLA sfusion related Acut /granulocyte antibo	e Lung injury (TRALI) by donor
	- Desp proce HIV mala - vCJI	edures, infections in HTLV 1 & 11 and ria) may, in rare inst transmission	ection and laboratory screening cluding Syphilis, Viral Hepatitis, other viruses and protozoa (e.g. cances, occur. thogens that are not tested for or

- Transmission of other pathogens that are not tested for or recognised.
- The risk of CMV transmission is minimal as the components are leucodepleted
- Sepsis due to bacterial contamination (reduced but not eliminated by bacterial screening)

IBTS/PMF/SPEC/0224	Ver 3	Page 5 of 7
--------------------	-------	-------------

Serious Adverse Reaction

Please inform the IBTS immediately about any event relating to suspected bacterial sepsis/ transfusion associated bacterial sepsis

Serious adverse reactions should be reported to:

National Haemovigilance Office 18 April 2021

Irish Blood Transfusion Service National Blood Centre James's Street Dublin 8

AND

Quality Assurance Manager


Irish Blood Transfusion Service

AT EITHER

National Blood Centre James's Street Dublin 8

<u>OR</u>

Munster Regional Transfusion Centre St Finbarr's Hospital Douglas Road, Cork Jerity when in Use. Stat JS.



N.B. Stated volume for illustration purposes only.

APPENDIX II

